Eli Lilly and Company announced Oct. 8 that a second look at an experimental drug therapy called solanezumab that targets mild to moderate Alzheimer’s disease, found the cognitive decline in study participants slowed by 34 percent. A full report and study results can be found here. http://www.seniorjournal.com/NEWS/Alzheimers/2012/20121009-Alzheimers_Patients.htm